Mavacoxib | CAS No. 170569-88-7

Mavacoxib

Basic Information

View in Editor

CAS Number

170569-88-7

Molecular Formula

C16H11F4N3O2S

Molecular Weight

385.34 g/mol

Chemical Classification

Basic Chemical Raw Materials Organic Chemicals Carboxylic Acids

Basic Chemical Raw Materials Organic Chemicals Amines

Basic Chemical Raw Materials Organic Chemicals Heterocyclic Compounds

Pharmaceutical Chemicals Pharmaceutical Intermediates Heterocyclic Intermediates

Fine Chemicals Dyes and Pigments Organic Dyes

Fine Chemicals Surfactants Anionic Surfactants

Fine Chemicals Specialty Chemicals UV Stabilizers

Agricultural Chemicals Pesticides Herbicides

Basic Physical Properties

SMILES

View in Editor

C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)F

InChI

InChI=1S/C16H11F4N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)

InChIKey

TTZNQDOUNXBMJV-UHFFFAOYSA-N

LogP

3.3446000000000007

Topological Polar Surface Area

77.98 Å²

Hydrogen Bond Donor/Acceptor

2 / 5

Complexity

579

Synonyms & References

English

4-[5-(4-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL]BENZENE-1-SULFONAMIDE
4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
Mavacoxib
PHA 739,521
4-[5-(4-Fluorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide
Trocoxil
4-[5-(4-Fluoro-phenyl)-3-trifluoromethyl-pyrazol-1-yl]-benzenesulfonamide
BenzenesulfonaMide, 4-[5-(4-fluorophenyl)-3-(trifluoroMethyl)-1H-pyrazol-1-yl]-
PHA 739521
4-[5-(4-Fluorophenyl)-3-trifluoroMethyl-1H-pyrazol-1-yl] benzenesulfonaMide
BCP15454
Mavacoxib (USAN)
AKOS030241943
C16H11F4N3O2S
s6685
4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]-benzenesulfonamide
Mavacoxib [USAN]
4-(5-(4-Fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
4-[5-(4-fluorophenyl)-3-trifluoromethyl-1h-pyrazol-1-yl]benzenesulfonamide
Mavacoxib [USAN:INN]
D04863
CS-0068402
Q6794110
Benzenesulfonamide, 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-
AT19475
MAVACOXIB [EMA EPAR VETERINARY]
MFCD28138640
SCHEMBL212699
CHEBI:76207
DB-228997

MDL Number

MFCD28138640

FAQ

What regulatory guidelines apply to Mavacoxib (CAS: 170569-88-7)?

Mavacoxib (CAS: 170569-88-7) is regulated under GHS (Globally Harmonized System of Classification and Labeling of Chemicals) for its potential health and environmental hazards. In the European Union, it is subject to REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) for registration and safety assessment. Additionally, FDA (U.S. Food and Drug Administration) and EPA (U.S. Environmental Protection Agency) have specific requirements for its use and handling in the pharmaceutical industry and the environment.

Are there alternatives to Mavacoxib (CAS: 170569-88-7) in synthesis?

Yes, there are alternatives to Mavacoxib (CAS: 170569-88-7) in synthesis. Some common analogs include other NSAIDs (Nonsteroidal Anti-inflammatory Drugs) such as meloxicam and carprofen. Alternative reagents like arylpropionic acids and fenamates could also be explored for similar purposes. However, the choice of alternatives depends on the specific application and desired properties.

What is the market or research trend for Mavacoxib (CAS: 170569-88-7)?

The market for Mavacoxib (CAS: 170569-88-7) is growing due to its efficacy as a COX-2 selective inhibitor. Research trends focus on its therapeutic applications, particularly in veterinary medicine for pain management in animals. There is also ongoing interest in its pharmacokinetic properties and potential for developing new formulations to enhance its therapeutic effects. Recent studies are exploring its use in a broader range of species and conditions.

How should waste containing Mavacoxib (CAS: 170569-88-7) be handled?

Waste containing Mavacoxib (CAS: 170569-88-7) should be collected in appropriate containers and stored separately to prevent contamination. It is advisable to neutralize the waste to reduce its acidity before disposal. Incineration is a common method for disposing of pharmaceutical waste. Professional waste disposal services specializing in hazardous materials should be used to ensure compliance with environmental regulations. Proper labeling and documentation are crucial to meet legal requirements and ensure safe disposal.